Who are Preemptive Analgesia Of Dexmedetomidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nebulized lidocaine and dexmedetomidine, Oxymetazoline gel, ketamine- dexmeditomidine admixure, brimonidine 0.1% (Alphagan® P), Dexmedetomidine for sedation, transdermal clonidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/preemptive-analgesia-of-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Preemptive Analgesia Of Dexmedetomidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preemptive Analgesia Of Dexmedetomidine (Preemptive Analgesia Of Dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Anesthesia and Pain Management.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Preemptive Analgesia Of Dexmedetomidine (Preemptive Analgesia Of Dexmedetomidine) — China International Neuroscience Institution. Dexmedetomidine is a selective alpha-2 adrenergic agonist that reduces pain perception and provides analgesia through central nervous system effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Preemptive Analgesia Of Dexmedetomidine TARGET	Preemptive Analgesia Of Dexmedetomidine	China International Neuroscience Institution	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Nebulized lidocaine and dexmedetomidine	Nebulized lidocaine and dexmedetomidine	Ain Shams University	marketed	Local anesthetic and sedative-analgesic combination	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Oxymetazoline gel	Oxymetazoline gel	RDD Pharma Ltd	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
ketamine- dexmeditomidine admixure	ketamine- dexmeditomidine admixure	Kasr El Aini Hospital	marketed	Dissociative anesthetic with alpha-2 adrenergic agonist	NMDA receptor (ketamine); alpha-2 adrenergic receptor (dexmedetomidine)
brimonidine 0.1% (Alphagan® P)	brimonidine 0.1% (Alphagan® P)	Allergan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Dexmedetomidine for sedation	Dexmedetomidine for sedation	Southeast University, China	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
transdermal clonidine	transdermal clonidine	Peking University People's Hospital	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Preemptive Analgesia Of Dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/preemptive-analgesia-of-dexmedetomidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab